Acceleron Pharma Inc (NASDAQ: XLRN) was a top gainer in yesterday’s trading session, and closed the day with gains of 50.16%. This followed the company’s announcement that, its mid-stage study for Sotatercept, its treatment candidate for people with PAH (Pulmonary Arterial